Tumor Blueprints provide a detailed profile of a tumor’s molecular characteristics. By measuring an evidence-based collection of biomarkers, this important diagnostic tests for molecular changes in more than 300 genes and the levels of around 20 proteins (click here for more information). For women with recurrent or refractory ovarian cancer, a Tumor Blueprint can provide important new information to help guide their next treatment. It may also be informative for women who are newly diagnosed and are considering enrolling in clinical trials to gain access to potentially promising new therapies.
The Tumor Blueprint report can offer a wealth of information about the unique genetic changes in a patient’s cancer. These results can inform treatment choices, pointing to therapies that may have the best chances for success. In some cases, these genomic changes may qualify a patient for a clinical trial because they are predicted to make the tumor more sensitive to that investigational therapy. Because Tumor Blueprints match treatments with each patient’s tumor profile, they have the potential to greatly improve outcomes.
These tests and their interpretation do not stand still. Clearity scientists regularly survey the medical literature to incorporate the latest information about biomarkers and treatments into the Tumor Blueprint report and add new tests or biomarkers to the diagnostic testing panel.
The Clearity Foundation currently collaborates with three CLIA-certified clinical labs to perform the testing: Caris Life Sciences, NeoGenomics Laboratories and Foundation Medicine. Typically, these diagnostics take two to three weeks to process.
Clearity summarizes the results from each laboratory into one report, which is sent to patients and their physicians. This comprehensive report is available online and provides information about the drugs that match the tumor profile and the reasons they match – all accessible by a mouse click. This evidence comes from clinical research studies that have shown a correlation between protein levels or genetic changes and drug effectiveness. As part of this analysis, Clearity compares each patient’s results to those of other ovarian cancer patients in the Clearity database.
In addition to their Tumor Blueprint reports, patients have access to Clearity’s staff, who provide input fueled by their expertise in ovarian cancer molecular and cellular biology. These important consults help them understand their results and the unique nature of their cancer, as well as potential treatments and clinical trial options.
Clearity does not provide medical advice about which treatments they should receive. Instead, our staff explain Tumor Blueprint results and provide potential questions, and other information, which patients can discuss with their physicians.